Drug intelligence / Profile preview

ONCOARON

Development stage: Preclinical
Lead developer: AronPharma
Modality: Small Molecules
Administration: Oral

Overview

ONCOARON is a nutraceutical candidate developed by the Polish biotechnology company AronPharma, specifically designed to prevent and minimize the adverse side effects associated with radiotherapy in cancer patients. Formulated as a food supplement, it leverages the bioactive properties of polyphenols and anthocyanins, likely derived from standardized extracts of *Aronia melanocarpa* (chokeberry). The mechanism of action involves the neutralization of reactive oxygen species (ROS) generated by ionizing radiation, thereby reducing oxidative stress and inflammation in healthy tissues. By providing radioprotective effects, ONCOARON aims to improve treatment tolerance and enhance the overall quality of life for oncology patients during their therapeutic regimen.

Brand names: ONCOARON

Beyond the preview

Go deeper on ONCOARON.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ONCOARON.

Explore the full profile